From our survey

How commercial insurance typically handles TMS, explained

If you carry a health plan through work or the marketplace and live with depression that medication has not resolved, there is a device-based treatment you may be able to get covered and may never have heard of. It is called transcranial magnetic stimulation, or TMS. This explainer covers what it is, how commercial insurers commonly handle it, and how to find out what your own plan will do, so that "I did not know that existed" is not the reason you never tried it.

The awareness problem

This summer our publisher funded a survey, and 443 adults across ten Midwest states completed it. Among its questions was a two-part item on TMS: did people know what it was, and did having a drug-free option matter to them?

Drug-free care mattered to 64 percent. Only 25 percent, a quarter, could explain TMS. The largest single group, just over half of respondents, did not know TMS but did care about drug-free treatment.

The panel's validation is complete, so those figures are final. The payer mix: commercial insurance was the most common coverage, reported by 39 percent of respondents, narrowly ahead of Medicaid at 37 percent, in a question that allowed more than one answer. For the 173 respondents on commercial plans, drug-free care mattered even more, at 71 percent.

What TMS is

During TMS, a coil set against the head sends brief, focused magnetic pulses into areas of the brain involved in regulating mood. It is FDA-cleared as a medical device for adults with major depressive disorder who have not gotten adequate relief from antidepressants. Devices are cleared rather than approved, a regulatory distinction worth knowing when you compare it with drug treatments.

What a course typically looks like:

• An initial session in which the clinician finds the right location and strength for your pulses.
• Treatment sessions on weekdays for several weeks, each visit taking a few minutes up to nearly an hour, by protocol.
• You remain awake and alert, with no anesthesia, and can usually drive yourself home.
• Common side effects include headache and scalp discomfort. Seizures are rare but serious, which is why providers screen beforehand.

TMS is drug-free in the sense that the treatment itself is not a medication. Many patients continue their antidepressant during a course. Decisions about medication belong with your prescriber.

How commercial plans commonly approach TMS

Every plan is different, and you must check your own. That said, many commercial insurers have written medical policies for TMS, and those policies tend to share a common structure.

Prior authorization. Most plans require approval before treatment starts. The TMS provider usually submits the request.

A diagnosis requirement. Coverage is typically limited to major depressive disorder, often of a certain severity, confirmed by a qualified clinician.

Documented medication history. Policies often require evidence that you have tried a set number of antidepressants, at adequate doses and for adequate lengths of time, without enough improvement, or that you could not tolerate them. The exact number varies from plan to plan.

Psychotherapy history. Some policies also ask for evidence of a trial of evidence-based talk therapy.

Exclusions. Policies usually list conditions that rule TMS out, such as certain implanted metal devices near the head or a seizure history, and may exclude some diagnoses.

Session limits and re-treatment rules. Plans commonly cap the initial course and set criteria for a repeat course if depression returns.

Cost-sharing. Even when TMS is covered, deductibles, copays, and coinsurance apply. Because a course involves many sessions, those costs can add up. Ask for an estimate up front.

How to find out what your plan does

• Search your insurer's website for its "medical policy" or "clinical policy" on transcranial magnetic stimulation. Many insurers publish these.
• Call member services and find out if your specific plan covers TMS for depression, whether prior authorization is required, and which providers near you are in network.
• If you get coverage through a large employer, find out from HR if the plan is self-funded. Self-funded plans may follow different rules from fully insured ones.
• Ask any TMS practice you contact whether they are in network, whether they submit prior authorization, and what your likely out-of-pocket cost would be.

If you are denied

A denial can often be reversed. Start by requesting the reason on paper. Common reasons include missing documentation of prior treatments. Your provider can often resubmit with fuller records or request a direct doctor-to-doctor call with the insurer's reviewer. You also have appeal rights, which your plan's denial letter should explain.

Patience with process is common. Just over half of our survey respondents preferred insured care with extra hoops to a simpler route they paid for themselves. And for 85 percent, coverage ranked among the top two things in choosing where to get care.

Where TMS fits among other options

TMS is one of several paths for depression that medication has not resolved. Spravato, an esketamine nasal spray, is FDA-approved for depression that resists standard medication and is administered under monitoring in certified clinics. Being a drug, it does not meet the goal of someone set on avoiding medication. Brain Recovery Centers has a rundown of the way Spravato sessions run for comparison. Talk therapy is drug-free and often recommended alongside other treatments. A psychiatrist can explain which options suit your history.

The best way in is usually your own doctor. A word from their own physician, 74 percent of respondents told us, would be the thing that gets them to try something new. You can open that door with one sentence: "I would like to explore non-medication options. Would TMS make sense for me?"

Use this as background, not as medical advice. Some people are not helped by any given treatment, TMS included.

Should depression bring you to thoughts of suicide, reach out right now, not after the insurance call. Pick up the phone or send a text to 988 right away. Nobody pays to use the Suicide and Crisis Lifeline, and it never closes.

Methodology

The survey cited here was ordered and funded by the publisher. Pollfish hosted it on its consumer panel; it stopped taking responses on June 23, 2026, at n=443, all respondents aged 18 to 64, from Ohio, Oklahoma, Minnesota, Indiana, Iowa, Kansas, Wisconsin, Nebraska, Illinois, and Missouri. Only the commercial insurance group is reported separately, and all figures are final after validation.